Sort
51,593 grants matching “hepatitis”
reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
$932,305Jose Szapocznik · University Of Miami School Of Medicine · R01 · FY2022 · DA
Endocannabinoids And Appetitive Functions
$931,718George Kunos · National Institute On Alcohol Abuse And Alcoholism · Z01 · FY2008 · AA
HCV Replication and Immunity
$931,641Christopher M. Walker · Research Inst Nationwide Children'S Hosp · U19 · FY2009 · AI
An Interdisciplinary Approach to HIV and Other Infectious Diseases of Drug Users
$931,499Sherry Deren · National Development And Research Institutes, Inc. · P30 · FY2008 · DA
Molecular heterogeneity of liver cancer and its clinical impacts
$930,599Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Strategies for improving early detection, diagnosis and treatment of liver cancer
$930,599Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Molecular mechanisms of MASHNASH-related hepatocellular carcinoma
$930,599Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Gulf Longitudinal Follow-up (GuLF) Study
$930,455Dale P Sandler · National Institute Of Environmental Health Sciences · ZIA · FY2023 · ES
Retinoid Metabolism and Alcohol Induced Disease
$930,354William S Blaner · Columbia University Health Sciences · RC2 · FY2009 · AA
Integration of HIV/AIDS, Viral Hepatitis, STD, and TB Programs
$930,271James W Gillan · Guam Department/ Health/Social Services · U52 · FY2014 · PS
Trial to Assess Chelation Therapy (TACT)
$929,729Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach) · U01 · FY2008 · HL
Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism
$929,121Byoung-Joon Song · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2021 · AA
FOCUS Data Coordinating Center
$928,989Michael L. Terrin · University Of Maryland Baltimore · U01 · FY2007 · HL
Studies of Rare Cancers
$928,330Louise Brinton · Division Of Cancer Epidemiology And Genetics · ZIA · FY2015 · CA
A Randomized Controlled Trial to Evaluate the Safety
$927,493University Of Southern California · M01 · FY2004 · RR
Preclinical Development of a Novel and Powerful Immunotherapeutic
$926,922Susan Dana Jones · Immurx Llc · R44 · FY2011 · AI
Novel Therapy for Amyotrophic Lateral Sclerosis
$926,669David E Smith · Angion Biomedica Corporation · R44 · FY2010 · NS
Project 3 - Flavivirus - UTMB
$926,569Pei-Yong Shi · University Of Alabama At Birmingham · U19 · FY2021 · AI
A Therapeutic Vaccine for Chronic Hepatitis B
$926,325David R. Milich · Vlp Biotech, Inc. · R44 · FY2012 · AI
The Hepatitis Care Connection Program (Hep-Care Connect)
$925,999David L Wyles · University Of California, San Diego · U51 · FY2013 · PS
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and Morbidity
$925,831Wen Xie · University Of Pittsburgh At Pittsburgh · R35 · FY2019 · ES
Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine.
$925,300Nhi Khuong · Lumen Bioscience, Inc. · R42 · FY2024 · AI
Novel Ondansetron Formulation for Combination Treatment of Psychostimulant Abuse
$924,518Tong H Lee · Duke University · RC2 · FY2009 · DA
Noninvasive urinary monitoring of NASH by activity-based nanosensors
$923,177Eric Kai Huang · Glympse Bio, Inc. · R44 · FY2019 · DK
Human Polycystic Kidney Disease
$923,157University Of Colorado Denver · P01 · FY2001 · DK